Finance

Lists
PVLA:NASDAQ
Palvella Therapeutics Inc
$150.39
0.00%
(0.00) 1D
Sep 10, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PVLA...
Mkt. cap
2.17B
Avg. vol.
185.82K
Volume
5.00
52-wk high
$161.38
52-wk low
$53.30
EPS
-$4.82
Beta
-0.25
Shares outstanding
14.41M
No. of employees
29
Mkt. cap
2.17B
Avg. vol.
185.82K
Volume
5.00
52-wk high
$161.38
52-wk low
$53.30
EPS
-$4.82
Beta
-0.25
Shares outstanding
14.41M
No. of employees
29
News stories
From web sources and news partners
About Palvella Therapeutics Inc
CEO-
Employees29
Founded-
Headquarters-
SectorBiotechnology
Websitepalvellatx.com
Analyst ratings
Based on 10 analysts giving stock ratings to PVLA in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for PVLA in the last 3 months.
Highest
Current $150.39
$270.00 (+79.53%)
Average
$233.20 (+55.06%)
Lowest
$205.00 (+36.31%)
Analyst
Recommendation
Action
Price target
Projected
Date
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
$240.00
+59.6%
09/10/2026
Andrew Fein
H.C. Wainwright
Buy
Maintained
$270.00
+79.5%
08/05/2026
Trevor Allred
Oppenheimer
Buy
Reiterated
$210.00
+39.6%
08/05/2026
Danielle Brill
Truist Financial
Buy
Reiterated
$207.00
+37.6%
08/05/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$236.00
+56.9%
08/05/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$232.00
+54.3%
08/05/2026
Jeet Mukherjee
BTIG
Buy
Maintained
$215.00
+43%
08/04/2026
Ritu Baral
TD Cowen
Buy
Maintained
$267.00
+77.5%
08/04/2026
Annabel Samimy
Stifel Nicolaus
Buy
Reiterated
$250.00
+66.2%
06/24/2026
Albert Lowe
Craig-Hallum
Buy
Reiterated
$205.00
+36.3%
06/22/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$240.00
+59.6%
05/20/2026
Sudan Loganathan
Stephens
Buy
Initiated
$220.00
+46.3%
05/11/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
$220.00
+46.3%
03/02/2026
Catherine Novack
JonesTrading
Buy
Maintained
$209.00
+39%
02/24/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
6.53M
7.12M
9.33M
12.47M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.65M
4.18M
5.52M
8.93M
Operating expense
10.18M
11.30M
14.86M
21.40M
Total operating expenses
10.18M
11.30M
14.86M
21.40M
Operating income
-10.18M
-11.30M
-14.86M
-21.40M
Other non operating income
-286.00K
-191.00K
54.00K
-122.00K
EBT including unusual items
-11.34M
-12.71M
-15.77M
-21.87M
EBT excluding unusual items
-11.34M
-12.71M
-15.77M
-21.87M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-11.34M
-12.71M
-15.77M
-21.87M
Net profit margin
-
-
-
-
Earnings per share
-1.03
-1.08
-1.20
-1.52
Interest and investment income
628.00K
520.00K
1.07M
1.96M
Interest expense
-1.51M
-1.74M
-2.04M
-2.31M
Net interest expenses
-882.00K
-1.22M
-966.00K
-343.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps